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Chapter 1 
-Background and Aim of the Study Project- 
 
  
 Classification of chronic lung disease (CLD) in children has traditionally been characterized 
by a clear distinction between cystic fibrosis (CF), the most common lethal inherited genetic 
disorder affecting 1 in every 2500-3500 live births worldwide (1), and less common “non-CF” 
disorders. The latters represent a heterogeneous group of several conditions with different 
etiologies, but with overlapping clinical features (2). Despite complete agreement on definitions has 
not been achieved, non-CF CLD generally describes a clinical syndrome characterized by 
symptoms of chronic endobronchial suppuration with or without radiological evidence of 
bronchiectasis at chest high-resolution computed tomography (HRCT) (3). Prevalence of non-CF 
CLD widely varies among countries, with peaks of one in 68 children in central Australia (4), and 
significantly lower prevalence in Europe, where approximately one in 7’440 children aged less than 
15 years is reported to be affected by one of these conditions (5). 
 Despite neglected and often still considered orphan diseases, pediatric non-CF chronic lung 
disorders are responsible of relevant burden for both families and health professionals. Indeed, these 
conditions still represent an important cause of respiratory morbidity in both developed (6) and 
developing (7) countries, with some affluent countries even reporting childhood fatalities (8). As a 
consequence, considerable stress, anxiety and depression have been reported in primary caregivers 
who look after these patients (9), and economic costs due to the frequent need for healthcare 
resources utilization are increasingly appreciated (10). 
 In the assessment of a child with chronic symptoms of endobronchial suppuration, i.e. wet 
cough and recurrent respiratory exacerbations with evidence of bacterial infection or colonization, a 
conclusive diagnosis may be cumbersome to achieve, as a number of different etiologies may 
underlie similar clinical presentations. Apart from CF, bronchiectasis and CLD may derive from a 
variety of conditions including recurrent aspiration, mucociliary dysfunction (mainly primary 
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ciliary dyskinesia, PCD) and primary or secondary immune deficiencies (3). The assessment of 
respiratory impairment in these conditions has traditionally relied on few tools which allow the 
evaluation of both lung function and structure and that are used for monitoring disease evolution 
and for modulating treatment (11). Despite the traditional dichotomy in assessing respiratory 
disease has been represented by the evaluation of lung function impairment on one side and by the 
visualization of lung structural damage on the other, an active search has been performed in order to 
find new and more sensitive biomarkers aimed at overcoming the limits of currently used diagnostic 
tools. This search has provided several promising results, particularly the metabolomic profiling of 
exhaled breath condensate, which has proven useful in differentiating respiratory phenotypes 
through the recognition of specific markers (12). These findings will hopefully lead towards 
diagnostic tools able to characterize, at a molecular level, different respiratory conditions and to 
provide a detailed definition of borderline phenotypes. 
Although justified in order to better monitor progression of lung impairment, these efforts aim to 
improve the management of only one, even though essential, aspect of pediatric CLD: the 
respiratory involvement. Nevertheless, an often unmet need in non-CF CLD children is a more 
global approach, taking into account other relevant issues such as growth, nutrition and 
psychological aspects, sometimes underestimated by pediatric respiratory physicians. Indeed, while 
in CF the involvement of the gastrointestinal tract and other organs entails a traditionally systemic 
approach to patients’ care, in non-CF respiratory conditions this issue is often neglected and also 
research in the field results to be relatively sparse. However, an increasing awareness is emerging 
regarding the need to adequately address nutritional status and growth in non-CF chronic 
respiratory disease of childhood, due to the strong relationship with lung impairment and to the 
evidence that these two elements may deeply influence each other. Furthermore, unlike other 
chronic conditions, in non-CF CLD and bronchiectasis poor attention has been dedicated to the 
impact of the disease on patients’ life. Quality of life (QoL), particularly health-related QoL 
(HRQoL), represents a crucial parameter to assess disease severity, efficacy of treatments and to 
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highlight areas of possible improvement in patients’ care. Indeed, despite the clinical manifestations 
of different chronic respiratory disorders in children may sometimes overlap (e.g. wet cough, 
dyspnea, fatigue), their impact on patients may vary significantly. Hence, specific evaluation tools 
are needed in order to standardize QoL assessment for both clinical and research purposes. 
Given these premises the main aims of this phD thesis are: 
1. To evaluate currently used and emerging tools in the diagnosis and monitoring of pediatric non-
CF CLD; 
2. To assess the role of nutritional status assessment in the management of non-CF CLD children. 
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Chapter 2 
-Chronic lung disease diagnosis and monitoring: current limits and potential new tools- 
 
2.1 Lung disease monitoring: pulmonary function versus pulmonary structure 
 In comparison to other organs which lend themselves to easy monitoring, e.g. serum 
creatinine in renal disease or liver function tests and imaging in liver disorders, lung is far more 
elusive, particularly in children. Therefore, to meet the clinicians’ need to assess and monitor lung 
function and structure, the development of reliable tools able to non-invasively evaluate these 
crucial components represents a research priority and a still open challenge (13). 
Pulmonary function tests (PFTs), namely spirometry, represent the most commonly used tool for 
diagnosis and monitoring of respiratory diseases both in children and adults. Nevertheless, PFTs are 
relatively insensitive markers of early disease and fail to detect changes in the peripheral airways 
(14). Spirometry is further limited by the high dependence on patient’s cooperation and by the lack 
of robust normal values in the infant population. Finally, there is increasing recognition that there 
may be structural lung damage on HRCT in children with normal spirometry, both in CF (15) and 
non-CF CLD (14). In this setting, the search for more sensitive measures of lung function 
impairment has led to an increasing interest in the lung clearance index (LCI) derived from 
multibreath washout tests (MBW). LCI is defined as the number of volume turnovers of the lungs 
required to reduce an inert gas to 1/40th of its starting concentration and is increased in many 
conditions, such as CF and asthma (16,17). It is non–effort dependent, and therefore it is applicable 
also to younger age groups who are typically unable to perform spirometry. Moreover, a growing 
body of literature supports the role of LCI as an earlier marker of lung impairment than spirometry 
in several chronic respiratory conditions, particularly with regard to distal airway disease. Of 
course, most of the available evidence derives from CF studies that showed that LCI becomes 
abnormal earlier than spirometry, and correlates significantly well with forced expiratory volume at 
1 second (FEV1) in later-stage disease (16,18). Studies in non-CF CLD are less conclusive. A 
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British study showed that, in adults with non-CF bronchiectasis, LCI is associated with spirometric 
airflow obstruction and may discriminate between patients and healthy subjects (19). Similarly, 
when assessed in PCD, LCI was altered even in presence of normal FEV1 (20), and was more 
sensitive than FEV1 in detecting structural abnormalities (21). Nevertheless, a comparative study of 
LCI, HRCT and spirometry in CF and PCD found that, unlike CF, LCI does not correlate with 
HRCT parameters in PCD, suggesting that it is not a sensitive test of airway disease in advanced 
PCD lung disease (22). 
If lung function assessment still relies on spirometry, a non-invasive tool limited by low sensitivity 
in evaluating distal airways and early disease, structural evaluation is based on a highly sensitive 
technique that provides detailed imaging of lung anatomy, i.e. computed tomography (CT). Chest 
CT, particularly HRCT, has become the imaging technique of choice for the evaluation of lung 
abnormalities at any age (23,24). However, despite its high efficacy in providing detailed images of 
pulmonary structure, CT has been criticized for its ionizing radiation burden and the possible 
consequences of cumulative doses, particularly deriving from frequent follow-up examinations in 
patients with chronic disorders, in pregnancy, and during childhood (25). Several surveys on the 
effects of repeated CT examinations have demonstrated that lifetime cancer risks are cumulative 
and not negligible, even though the consequences of low levels of exposure have not been clearly 
elucidated (26,27). In this setting, chest magnetic resonance imaging (MRI) is being increasingly 
regarded as a reliable radiation-free technique for the assessment and follow-up of several chest 
disorders (28-30). Application of MRI in lung imaging has long been limited by technical problems, 
namely a low signal-to-noise ratio because of the low proton density of the lung, and artifacts 
deriving from cardiac and breathing motion (31). Over the last decade, a growing body of literature 
has been produced to compare the efficacy of chest MRI, mainly 1.5-T MRI, with other traditional 
imaging techniques in children or adults with respiratory conditions (30,32-35). These studies 
mostly agreed in the conclusion that MRI is comparable to conventional chest x-ray and CT, and 
could represent a reliable radiation-free option in lung disorders. 
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In the last years, we focused our attention on the possibility to adopt high-field 3.0-T MRI, which 
shows better temporal and/or spatial resolution and faster acquisition times when compared to 1.5-T 
MRI (36), in the assessment of lung structural impairment in patients with non-CF CLD. 
Particularly, we demonstrated that chest MRI is as effective as HRCT in assessing the extent and 
severity of lung abnormalities in children with PCD, primary immunodeficiencies and recurrent 
pneumonia (37). We also extended the use of this non-invasive technique to a particular category of 
patients, namely subjects with ataxia telangiectasia (AT), a rare autosomal recessive disease 
characterized by heightened sensitivity to ionizing radiations, increased risk of developing 
lymphoid malignancies, and the progressive development of CLD as a major cause of morbidity 
and mortality (38). An imaging tool able to assess lung structural damage is virtually lacking in AT, 
as HRCT is not applicable to patients due to the ionizing radiation burden (25). Therefore, in fifteen 
patients with AT, we assessed lung structural abnormalities by means of chest high-field MRI, and 
found abnormalities such as bronchiectasis, mucous plugging or consolidations in all subjects either 
they were symptomatic or not. Hence, given that AT patients should avoid imaging techniques 
entailing radiation exposure, we concluded that chest MRI should be proposed in the diagnostic 
pathway for AT pulmonary disease assessment (39). 
The increasingly accepted reliability of chest MRI in visualizing lung structural abnormalities both 
in CF and non-CF CLD has raised the possibility of using such tool in comparison studies. Among 
non-CF chronic respiratory conditions, PCD is a rare autosomal recessive disease whose 
management is widely mutuated from CF care, due to phenotypical similarities between the 
conditions (40). Therefore, we performed a comparative assessment of clinical, functional, 
microbiological and MRI findings in PCD and CF patients in order to evaluate different expression 
of lung disease.  
 
The results of this analysis were included in a study that has been recently accepted for 
publication in the Italian Journal of Pediatrics. 
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2.2 Old and new biomarkers 
 The broad spectrum of clinical presentation and the poor correlation between routinely used 
functional and structural parameters and the pathogenic mechanisms underlying non-CF CLD has 
made the identification of objective biomarkers an urgent research priority. The ideal biomarker 
which could potentially revolutionize clinical management of children with chronic respiratory 
disorders should be cheap, easy, non-invasive, reproducible and sufficiently informative in order to 
be helpful in diagnosis, phenotyping, management or treatment of respiratory diseases. 
The gold standard method to obtain airway samples and quantify inflammatory markers both in CF 
and non-CF lung disease is still represented by broncho-alveolar lavage (BAL) (41,42). 
Nevertheless, its invasivity and cost, the need for general sedation, and the potential risks of the 
procedure strongly limit the use of such tool, particularly in pediatric settings where chronic 
patients are followed-up and inflammatory markers are periodically monitored. Therefore, the need 
for less invasive means of sampling airway surface liquid has oriented research towards the 
development of new technologies, among which an increasing interest has been raised by the 
technique of exhaled breath condensate (EBC). 
Collection of EBC is generally performed by asking patients to breathe quietly through a chilled 
tube connected to a condenser with a saliva trap to reduce salivary contamination, in order to obtain 
a liquid mostly consisting of water vapor with a small fraction of secretions. This condensate is then 
promptly frozen in liquid nitrogen to suppress metabolism and preserve metabolite concentrations 
(43). The analysis of such samples relies on highly sensitive methods, particularly metabolomics, 
whose application has proven feasible and promising in several fields of medicine (44). 
Metabolomics basically aims at identifying specific metabolic profiles through the identification of 
numerous low-molecular-weight endogenous metabolites by means of mass spectroscopy or nuclear 
magnetic resonance (44). Application of metabolomics to pediatric respiratory disorders has 
produced some evidence that supports its usefulness in characterizing airway biochemical 
fingerprints, and potentially providing elements for the identification of new pathways, particularly 
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in asthma (45). Unfortunately, despite the great interest raised, inadequate diffusion of both 
metabolomics and EBC in pediatric respiratory centers has limited the research in this field, and, till 
now, pediatric CLD, including CF, has been poorly investigated with these tools. 
Nevertheless, moving from the observation that metabolomics recognizes markers separating 
children with stable or unstable CF (46), our group recently showed that nuclear magnetic 
resonance discriminates PCD from CF subjects, suggesting that distinct inflammatory and 
metabolic processes likely generate different metabolites that may be found in the EBC from 
patients with the two conditions (12). Confirming the extraordinary potential of metabolomics in the 
characterization of chronic respiratory diseases, this finding further supports the role of noninvasive 
assessment of EBC for identifying different CLD phenotypes and for tailoring of treatment. 
 In the field of non-invasive biomarkers in respiratory medicine a relevant role has been 
gained, over the last two decades, by nitric oxide (NO), a biological mediator that was first 
described as a vascular smooth muscle relaxant and was subsequently found to be present in the 
expired breath of animals and humans (47). Nitric oxide has several effects in the respiratory tract, 
including smooth muscle relaxation, blood flow regulation and modifications of ciliary beat 
frequency, mucus secretion and cell-mediated immune processes (48). Lower respiratory tract 
typically shows decreased NO levels in comparison to the upper airways, where its concentrations 
achieve the maximum in the paranasal sinuses. The possibility of measuring NO in children, 
combined with the availability of relatively cheap portable devices, has progressively made NO 
assessment a crucial part in the diagnosis and management of several pediatric respiratory disorders.  
Nitric oxide measurement includes fractional exhaled NO (FeNO) and nasal NO (nNO), which have 
proven useful for different purposes in different conditions. FeNO analysis is well validated and far 
more widespread than nNO measurement due to its main clinical application, represented by the 
evaluation, both at diagnosis and during the follow-up, of children with bronchial asthma (49). 
Indeed, as a marker of airway inflammation, FeNO is valuable in monitoring patients’ response and 
adherence to maintenance therapy and has been shown to be helpful in predicting both onset and 
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exacerbations of asthma (49). Application of FeNO to other respiratory conditions is substantially 
limited and available evidence is scarce, especially in children. Despite some studies have been 
conducted in order to evaluate the utility of FeNO in community acquired pneumonia, 
bronchiectasis, bronchiolitis and diffuse lung disease, data are far too limited to support conclusive 
recommendations or to allow translation of this tool to the routine management of these conditions 
(49). 
On the other hand, nNO has been proposed as an additional tool in diagnosis, treatment, and 
management of several airways diseases. Nevertheless, we recently reviewed the available literature 
regarding nNO measurement application to pediatric respiratory diseases, particularly 
rhinosinusitis, allergic rhinitis, adenoidal hypertrophy and more severe chronic conditions such as 
CF and PCD. What we concluded is that, despite a growing body of evidence pointing towards the 
utility of nNO in the diagnostic work-up of several disorders, this biomarker has currently one 
major application that is represented by the screening of PCD (50). Indeed, the markedly reduced 
nNO concentrations typically found in PCD is a well-known feature of the condition, and is often 
useful in clinical practice to orientate further diagnostic testing and to support diagnosis of patients 
with atypical PCD phenotype and normal ciliary ultrastructure (51,52). Conversely, nNO 
measurement is of limited value for other respiratory disorders, and further research is needed to 
recommend the inclusion of such biomarker in the management protocols of other pediatric 
respiratory conditions. 
 
Findings from this analysis of current and potential nNO applications were published in 
Pediatric Pulmonology. 
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2.3 Everyday impact of respiratory disease: measuring quality of life 
 Monitoring chronic respiratory diseases has been traditionally focused on the periodical 
assessment of clinical, functional and imaging outcomes (2). However, likewise other chronic 
conditions, these parameters are inadequate to evaluate the impact the disease has on children’s 
everyday physical, social, emotional and school functioning (53). Furthermore, prescribed 
treatments, with the related burden on patients’ daily activities, is often given insufficient 
consideration, thus entailing an incomplete perception of disease control, comprehensively 
intended. 
Therefore, in the last decades, the role of quality of life (QoL), particularly health-related QoL 
(HRQoL), has increasingly gained relevance in the management of pediatric chronic patients. This 
has determined an effort in standardizing evaluation tools to quantify the disease impact on patients, 
and therefore disease-specific questionnaires for pediatric patients or their parents have been 
developed (53-55). 
Several tools are currently available for the assessment of QoL in chronic respiratory conditions 
such as asthma (53) and CF (54), and represent useful outcome measures for both clinical and 
research purposes. On the contrary, questionnaires specifically developed for the assessment of 
patient-reported outcomes (PRO) in non-CF CLD have been proposed only recently. Quittner and 
coworkers, moving from the experience in CF pediatric care, developed the QoL Questionnaire-
Bronchiectasis (QoL-B) as the first specific tool for non-CF bronchiectasis that showed a good 
reproducibility and reliability in a validation study (55). Nevertheless, efforts in assessing QoL in 
other non-CF chronic respiratory disorders have been less remarkable, and, particularly in PCD 
management, a well-designed PRO measure has long been lacking. 
The development and validation of a disease-specific PRO measure generally moves from the 
evaluation of the applicability of QoL evaluation tools originally thought for other conditions. 
Similar PRO measures including elements of specificity regarding the disease considered are then 
generally developed (55). Further steps include the assessment of reproducibility of the tools under 
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consideration and the evaluation of their efficacy in determining long-term QoL changes. We 
performed such evaluations in 20 PCD subjects followed-up at our center, in whom QoL was 
assessed at baseline and after 12 months by means of three commonly used questionnaires for 
chronic respiratory diseases, namely, the St. George’s Respiratory Questionnaire, the Medical 
Outcomes Study Short Form 36, and the Leicester Cough Questionnaire (56). Our main finding was 
that, both at baseline and after 12 months, PROs were not related to functional parameters. 
Therefore, we concluded that the adopted PRO measures are suboptimal to longitudinally track QoL 
in PCD, and new tools specifically developed for PCD children are urgently needed. 
Interestingly, this relevant gap in PCD management has been filled by an extremely recent study 
proposing the first HRQoL measure for PCD children considering general aspects common to other 
chronic lung disorders and also a wide spectrum of issues unique to this population (57). A major 
merit of this valuable QoL-PCD questionnaire is the underlying methodology, based on the 
recruitment of a wide, ethnically and socially heterogeneous sample of PCD subjects. Moreover, the 
PRO measures were evaluated at different ages, confirming the expected differences in patients’ 
perspectives. In particular, younger children have a less evident perception of the impact their 
condition has on social functioning, energy levels and vitality. Given the strengths of this new 
instrument, it is desirable that it will be soon adopted as an end-point for monitoring health 
outcomes in both clinical and research settings, in the perspective of an increasingly patient-
centered disease management. 
 
Our findings on the applicability of commonly used PRO measures in PCD children have 
been published in Chest. 
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2.4 Management algorithms: the example of esophageal atresia survivors 
 In most cases, managing children with non-CF CLD means dealing with rare or at least 
uncommon conditions that require specialist referral to provide standardized management 
approaches. Nevertheless, before expert consultation, patients are often managed by primary care 
health professionals who are seldom trained and confident enough to correctly assess and manage 
the disease and its related complications (58). In this scenario, structured pathways for clinical 
decision-making, including diagnostic procedures and even indications or timing for specialist 
referral are of primary relevance. The production of different pathways and algorithms clarified 
how to suspect, diagnose and manage a number of conditions under the wide umbrella of pediatric 
CLD (40,59). Particularly, a valuable example of management algorithm has been developed for 
chronic cough (60). Apart from providing physicians with an easy-to-use and helpful tool, recent 
high quality evidence suggests that in children with chronic cough the use of algorithms also 
improves clinical outcomes (61). 
As the need for useful clinical algorithms is particularly relevant in uncommon conditions, we 
focused our efforts on the standardization of behaviors in the management of respiratory 
complications deriving from a relatively rare disease, namely esophageal atresia (EA), for which 
robust evidence based on large populations is lacking. 
The dramatic improvement of perinatal care and of surgical techniques observed in the last decades 
has transformed EA, with or without tracheoesophageal fistula, from a frequently lethal 
malformation to a relatively treatable disease, with a consequent increase in the burden of long term 
complications, which more often involve the respiratory tract (62). Recurrent bronchitis, chronic 
cough and asthma-like symptoms represent the major clinical manifestations, together with lower 
respiratory tract infections, which may achieve an incidence of five episodes per year, particularly 
in the first years of life (63). These complications result in a respiratory impairment that, according 
to the available literature, is generally characterized by a restrictive rather than obstructive 
functional pattern and by morphological abnormalities mainly consisting of bronchiectasis and 
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consolidations (64). Furthermore, airway endoscopy findings, occasionally reported by some 
authors (65,66), have shown tracheo- and bronchomalacia to be the most frequently detected 
abnormalities. Despite still debated, the etiology of pulmonary manifestations following EA repair 
is likely multifactorial. First, the increased risk of premature birth in newborns with EA often 
entails the association of lung hypoplasia, tracheomalacia and other respiratory disorders typical of 
prematurity (67). Furthermore, available studies suggest that chronic asthma is likely elicited by a 
reflex mechanism, whereas repeated acid aspiration associated to gastroesophageal reflux and 
feeding difficulties may well explain the recurrence of lower respiratory tract infections (68,69). 
Finally, structural abnormalities of both the airways and the esophagus frequently persist after EA 
repair, contributing to alter pulmonary function (67). 
Despite several articles on the long-term respiratory complications of EA survivors have been 
published, available literature does not provide a shared executive protocol which could guide 
clinicians in the management of these patients. Particularly, even though descriptive studies have 
summarized the most typical functional and structural features of the condition, the available 
diagnostic tools have never been ordered in a management algorithm. Moving from these 
observations, we built a basic decisional pathway whose aim is to help clinicians in assessing the 
degree of respiratory impairment with a reasoned use of diagnostic tools, and, consequently, to 
choose the most appropriate follow-up. Of course, like all algorithms, our proposal is not meant to 
replace clinical judgment, but its daily application is highly desirable in order to verify its efficacy 
in driving physicians in the systematic approach to the chronic pulmonary manifestations of EA 
survivors. 
 
A review of the available literature, together with the mentioned proposal of a management 
algorithm for these patients, was published in Pediatrics and Neonatology. 
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Chapter 3 
-The role of nutritional status in children with chronic lung disease- 
 
3.1 Growth monitoring: the example of Primary Ciliary Dyskinesia 
 Despite apparently poorly linked, nutrition and respiratory symptoms are deeply interrelated. 
The raised energy expenditure deriving from the increased work of breathing typical of CLD may 
alter the metabolic balance of affected children significantly affecting growth. Similarly, chronic 
infection and poor pulmonary function also determine increased energy utilization (70). On the 
other hand, malnutrition decreases the strength of the respiratory muscles and impairs pulmonary 
defense against pathogens, increasing the risk of respiratory infections and thus leading to a 
dangerous “vicious circle” (70,71). 
Low body mass index (BMI) has been associated with impaired respiratory function and higher risk 
of death in patients with chronic obstructive pulmonary disease (COPD) (70), making nutritional 
status a crucial aspect to be assessed in the daily management of these subjects. Similarly, 
nutritional status of 2-year-old children with bronchopulmonary dysplasia has been shown to affect 
pulmonary outcomes in childhood (72). On the other hand, impaired lung function has been 
reported in children with history of premature birth and intrauterine growth retardation (73).  
In pediatric CF care assessment and monitoring of nutritional status represents one of the 
cornerstones of the clinical management. In particular, pancreatic insufficiency deeply affects 
somatic growth, and an association with worse respiratory function has been widely demonstrated. 
Indeed, nutritional deficiency secondary to malabsorption may lead to poor lung growth and 
increased susceptibility to infections (71), determining a more severe CF phenotype (74). 
Nevertheless, long-term activation of inflammation and chronic pulmonary disease with hypoxia 
has been shown to decrease IGF-I levels, providing another likely mechanism involved in CF 
children’s growth impairment (75). 
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Nutritional status in non-CF CLD has been less investigated and available studies are limited, also 
because of the difficulties in enrolling large and homogeneous populations and in progressively 
assessing growth for sufficient follow-up periods. Two studies have remarkably demonstrated that 
children with non-CF bronchiectasis show adequate somatic growth and stabilization of lung 
function over time (76,77). Conversely, data on the longitudinal progression of anthropometric 
parameters in patients with PCD are extremely sparse. Some authors have anecdotally reported 
progressive growth impairment during childhood (78), but the extremely limited sample size of 
such reports prevents from any generalization to the pediatric PCD population. 
The rationale behind a possible nutritional impairment in PCD substantially derives from the 
chronicity of the disease and the recurrence of upper and lower respiratory tract infections. Indeed, 
despite several PCD features are similar to CF, malabsorption, liver disease and diabetes that play 
major roles in CF malnutrition (71) are not seen in this rare condition (50). In order to verify the 
hypothesis that PCD children and adolescents receiving centralized care do not present significant 
abnormalities in growth parameters, we designed a wide multicenter study involving a total of 158 
PCD subjects from three European tertiary care centers, namely the Royal Brompton Hospital, 
London, UK, the Federico II University, Naples, Italy, and the Department of Pediatrics & 
Adolescent Medicine, Copenhagen, Denmark. The retrospective evaluation aimed at tracking the 
progression of lung function parameters and BMI over defined periods of two, four and six 
consecutive years. What emerged from our analysis was that early referral to a PCD center during 
preschool age is not associated to better spirometry or BMI. More importantly, the longitudinal 
assessment of our cohort showed that PCD children and adolescents receiving centralized care show 
steady BMI and stable spirometry during medium term follow-up. 
 
This study, which represented a fruitful collaboration between the three mentioned European 
centers, was conducted during a long-term research fellowship funded by the European 
Respiratory Society that allowed Dr. Maglione to attend the Department of Pediatric 
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Respiratory Medicine at the Royal Brompton Hospital in London, UK, under the supervision 
of Prof. Andrew Bush. The results of this study have been published in Pediatric Pulmonology. 
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3.2 Micronutrients, respiratory infections and chronic lung disease 
 The periodical recording of anthropometric parameters represents only a partial and quite 
limited approach to the problem of assessing nutritional status in children and adolescents with 
chronic respiratory disorders. In the last years, a growing attention has been given to the evaluation 
of micronutrients levels in a wide group of chronic respiratory (79,80) and non-respiratory 
conditions (81) and even in healthy children (82), in order to assess their role in affecting a number 
of health outcomes. 
In the field of pediatric respiratory diseases, what has gradually emerged over the last decade is that 
specific and sometimes multiple micronutrients deficits may significantly contribute to morbidity 
and mortality of respiratory disorders, as supported, for instance, by the link between acute lower 
respiratory infections and zinc deficiency (83). 
Most studies investigating the relationship between respiratory conditions and micronutrients have 
been conducted in developing countries, where the higher prevalence of malnutrition and of 
respiratory infections makes observational reports and nutritional interventions easier to perform. 
However, for most micronutrients, a robust body of evidence supporting specific effects on health 
outcomes is still lacking. Despite often moving from limited amount of studies, several metanalyses 
and literature reviews have been published in the last years, and interesting observations for 
selected vitamins and oligoelements have been provided.  
Zinc supplementation, for instance, has been widely investigated in order to assess its effect on the 
prevention of respiratory infections. Ten years ago Aggarwal and coworkers reviewed the available 
literature and concluded that zinc supplementation significantly decreases frequency and severity of 
respiratory diseases in children (84). More recently, this finding was confirmed by the analysis of 
18 studies conducted in developing countries which showed a reduction in lower respiratory tract 
infections and in mortality due to pneumonia in children supplemented with zinc (85). On the other 
hand, the effect of zinc supplementation in decreasing the duration of respiratory symptoms in 
children with pneumonia is much more controversial, with evidence in support of the efficacy of 
63 
 
zinc on the clinical course (86) and a trial even suggesting a negative effect biochemical parameters 
(87). 
Zinc supplementation has also been evaluated in association with another micronutrient whose anti-
oxidant and immunostimulatory properties are widely recognized, namely vitamin C. Particularly, 
combined supplementation of the two nutrients has proven to improve symptoms and shorten 
duration of airway infections such as common colds and, in developing countries, pneumonia (88). 
Nevertheless, a recent systematic review on the effect of vitamin C on respiratory tract infections, 
despite confirming a protective and therapeutic effect on both children and adults with pneumonia, 
suggested to limit supplementation only to subjects with documented low serum levels of vitamin C 
(89). 
Despite the raising interest towards a number of micronutrients, also including zinc and vitamin C, 
there is no doubt that the more relevant efforts have been dedicated to study the potential effects on 
respiratory and non-respiratory health outcomes of another micronutrient, namely vitamin D. 
The identification of vitamin D receptors on lymphocytes, monocytes and antigen-presenting cells 
has made definitely clear that this micronutrient plays a role in something more complex than the 
calcium, phosphorus and bone metabolism, providing new insights in its multiple functions (90). In 
particular, the ongoing characterization of the immunomodulatory pathways in which vitamin D is 
involved, is providing new evidence on its links with a number of respiratory conditions. Recent 
studies suggest that low serum vitamin D levels are associated to a higher risk of respiratory 
infections (91,92) and to increased mortality secondary to pneumonia (93). Although reports on the 
negative effects of hypovitaminosis D on respiratory health outcomes are increasingly available, 
results on the efficacy of vitamin D supplementation are far more controversial. In 2013, two 
systematic reviews analyzing the usefulness of vitamin D supplementation in preventing respiratory 
infections achieved different conclusions, preventing from any definite recommendation (94,95). 
The only accepted indication for high-dose vitamin D is tuberculosis, as there is evidence of a 
significantly quicker resolution of respiratory symptoms in affected patients (96). 
64 
 
In this scenario, we focused our attention on the assessment of serum vitamin D levels in children 
with PCD, in order to assess correlations with clinical outcomes and pulmonary function. Our 
analysis highlighted that hypovitaminosis D is a frequent finding in PCD and is associated with 
poorer QoL. 
 
The results of this study were published in the Italian Journal of Pediatrics. 
.
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Chapter 4 
-Conclusive remarks- 
  
 Despite less frequent than CF, pediatric non-CF CLD is responsible for a relevant burden for 
patients and families, with a significant impact on health-related social costs. Due to the primary 
involvement of the respiratory system, this heterogeneous group of disorders is typically managed 
by pediatric pulmonologists whose approach is traditionally centered on the assessment and 
monitoring of lung impairment, in terms of both functional and structural damage. Nevertheless, as 
in most pediatric chronic conditions, the physician’s task is to address the multiple aspects and 
implications of the disease, taking into account frequently neglected issues, such as, for instance, 
quality of life and nutritional status, aimed at a global approach in a patient-centered, rather than 
disease-centered perspective. 
In this scenario, our research was first oriented towards the analysis of currently used tools for 
diagnosis and monitoring of pediatric non-CF CLD in order to highlight their main limits and to 
evaluate potential new instruments. The most relevant findings from these studies regarded: 1) the 
possible clinical application of chest MRI in the assessment and monitoring of lung structural 
impairment in children with non-CF CLD, that would entail a reduction in the ionizing radiation 
burden associated with periodic CT examinations; 2) the limited applicability of PRO measures 
created for determined respiratory conditions to other disorders, particularly PCD, and the 
subsequent need for disease-specific QoL assessment tools; 3) the usefulness of specific algorithms 
in guiding the daily management of children with chronic respiratory diseases, particularly for 
establishing adequate follow-up of rare conditions. 
We successively focused on the evaluation of nutritional status in a subset of patients with non-CF 
CLD, namely PCD children and adolescents. Our data highlighted that, as hypothesized, patients 
receiving a centralized care show stable anthropometric parameters over a medium term follow-up. 
Nevertheless, when extended to the analysis of serum vitamin D levels, our evaluation showed the 
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deficiency of this micronutrient to be a frequent finding in PCD and to correlate to poorer QoL, 
suggesting the need for a systematic assessment of vitamin D status in these patients, in order to 
consider tailored supplementation.  
Taken together, our findings strengthen the importance of a global approach to the pediatric patient 
with non-CF CLD. Indeed, even though lacking the multisystem involvement typical of CF, non-CF 
CLD management cannot ignore aspects apparently disconnected from the respiratory disease, 
adopting a wide and comprehensive approach aimed at improving health, globally intended. 
Future research should hopefully confirm and extend our results, standardizing the proposed 
approach in disease-specific management algorithms, in order to verify their applicability and 
efficacy in improving health outcomes. 
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Chapter 5 
-Main Materials and Methods- 
 
MR scanning 
 MRI was performed with a 3.0-T MR scanner (Magnetom Trio, Siemens Erlangen, 
Germany), a maximum gradient strength of 40 mT/m, a slew rate of 200 mT/m/ms, and 32 
radiofrequency channels. We used a dedicated 12-element integrated matrix coil system that 
covered the whole thorax for signal reception. It consisted of 1 anterior and 1 posterior flexible 
phased-array coil, each containing a set of 6 receiver elements. The applied sequence was a T2-
weighted half-Fourier single-shot turbo spin-echo (HASTE) sequence, performed using an 
electrocardiograph-gating to reduce cardiac motion artifacts, and respiratory-gating by a navigator 
signal that monitored the diaphragm position. The field of view was patient-adapted. Sequence 
parameters were: repetition time/echo time/flip angle, infinite/92 milliseconds/150 degrees; 25 to 30 
slices; slice thickness, 5 mm; distance factor, 20%; transversal orientation (matrix, 380  256); 
acquisition time, approximately 90 seconds. Parallel imaging was used for all measurements using 
the GRAPPA (Generalized Autocalibrating Partially Parallel Acquisition) algorithm with an 
acceleration factor of 2 and 24 reference lines. No patient required sedation. Door-to-door time was 
5.5 minutes (range, 5–8). All MR studies were of diagnostic quality and were well tolerated. 
 
HRCT scanning 
 The HRCT scan was performed with a 4-slice CT scanner (Aquilion, Toshiba, Japan) and a 
bodyweight adapted protocol (adolescents: 120 kV, 140 mAs; children over 45 kg: 120 kV, 65 
mAs; children over 35 kg: 120 kV, 45 mAs; children below 35 kg: 120 kV, 30 mAs), with 1x4 mm 
collimation, 10 mm gap, 0.5 seconds rotation time, automatic exposure control, multiple inspiratory 
breath holds of 3 seconds each, with the patient in a supine position. Scanning extended from the 
lung apices to below the costophrenic angles. The field of view of each sequence was patient 
74 
 
adapted. Images were reconstructed using a high-resolution algorithm. The total time for acquisition 
of the images was approximately 5 minutes, including positioning of the patient. Contrast medium 
was not administered. For documentation of radiation exposure, the dose length product was 
recorded, and the effective dose and the weighted CT dose index were calculated. A lung window 
setting (+1500/-500 Hounsfield unit) was used for image analysis. Images were reviewed on a 
workstation (iMac MacOS 10.4/OsiriX v.2.7.5 32 bit). 
 
Image Evaluation 
 Both CT and MR scans were scored using the morphologic scoring system which was 
originally developed for CF by Helbich et al. (97), later modified by Puderbach et al. (33), and 
recently used also for the assessment of PCD lung disease (37). Maximum achievable total score 
was 25, indicating the most severe lung changes. For the purpose of quantifying the severity of 
PCD or CF lung structure deterioration, we arbitrarily divided the total MR score into three scores 
subgroups, i.e. 0-9, or mild; 10-18, or moderate; and 19-25, or severe lung damage, respectively. 
For the analysis of the specific CT and MR parameters included in the scoring system we referred 
to accepted definitions described in detail elsewhere (33). Furthermore, for the categories “severity 
of bronchiectasis” and “severity of peribronchial wall thickening”, we recorded the most prevalent 
degree of severity. It was not possible to assess peribronchial wall thickening in the presence of 
mucous plugging, and, if mucous plugging was seen within the periphery of a lung segment, 
bronchiectasis was scored also in that segment. Six lobes were examined, the lingula being scored 
as a separate lobe. In patients with situs viscerum inversus, the right lung was the lung in which the 
middle lobar bronchus and the corresponding middle lobe were identified at scans. 
 
Spirometry 
Forced vital capacity (FVC), FEV1, and forced expiratory flow between 25% and 75% of FVC 
(FEF25–75) were measured according to published criteria (98). Spirometry parameters were 
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expressed as percentage predicted and Z scores (99). FEV1 was the primary outcome parameter, and 
a Z-score < 1.96 was considered abnormal (100). 
 
Quality of life 
In order to assess HRQoL, patients with PCD aged ≥6 years completed the St. Georges Respiratory 
Questionnaire (SGRQ; 101), a disease-specific measure developed for asthma and COPD that has 
been validated also in children and adults with PCD (56,102). SGRQ score ranges from 0 to 100 
(100 indicating the maximum impairment). The youngest children were helped by their parents in 
answering the SGRQ questions. 
 
Vitamin D measurement 
A single determination of vitamin D levels, measured as total 25(OH)D, was performed on blood 
samples obtained between 08:00 a.m. and 09:00 a.m. after overnight fast, using the 
chemiluminescent method (Liasion, DiaSorin, Saluggia, Italy) (103). Vitamin D levels were 
categorized as being sufficient when >30 ng/ml (>75 nmol/L), insufficient between 20 and 30 ng/ml 
(50 and 75 nmol/L), and deficient when <20 ng/ml (<50 nmol/L) (90). 
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Chapter 7 
-Curriculum vitae- 
 
Main Research Fields:  
1) Management of pediatric non-CF chronic lung disease, particularly PCD, bronchiectasis and 
asthma; 
2) Assessment of lung structure abnormalities in PCD children and young adults by means of 
conventional and non-conventional imaging techniques, namely chest HRCT and MRI; 
3) Respiratory manifestations in children with gastrointestinal disorders, particularly gastro-
esophageal reflux disease, and esophageal atresia; 
4) Multidisciplinary management of children with severe neurological disability and nutritional 
impairment; 
5) Therapy of pediatric functional gastrointestinal disorders, particularly Irritable Bowel 
Syndrome. 
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